



(11) **EP 3 025 705 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 9/16 (2006.01)

(48) Corrigendum issued on:
28.11.2018 Bulletin 2018/48

(45) Date of publication and mention
of the grant of the patent:
24.10.2018 Bulletin 2018/43

(21) Application number: **14194774.7**

(22) Date of filing: **25.11.2014**

(54) **Stable ivabradine formulations**

Stabile Ivabradinformulierungen

Formulations d'ivabradine stable

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(43) Date of publication of application:
01.06.2016 Bulletin 2016/22

(73) Proprietor: **Sanofi İlaç Sanayi ve Ticaret Anonim**
Sirketi
İstanbul (TR)

(72) Inventors:
• **Adıyaman, Mustafa**
39780 Kırklareli (TR)

• **Oran, Umut**
39780 Kırklareli (TR)
• **Çakmak, Özkan**
39780 Kırklareli (TR)

(74) Representative: **Sevinç, Erkan**
İstanbul Patent A.S.
Plaza-33, Büyükdere Cad. No: 33/16
Sisli
34381 İstanbul (TR)

(56) References cited:
US-A- 5 296 482 US-A1- 2011 306 598
US-A1- 2013 084 335

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 025 705 B8